Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis
Open Access
- 25 August 2021
- journal article
- research article
- Published by Elsevier in Mucosal Immunology
- Vol. 15 (1) , 109-119
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Secretory IgA: Designed for Anti-Microbial DefenseFrontiers in Immunology, 2013
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel DiseasesThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humansJournal of Experimental Medicine, 2008
- Generation of Gut-Homing IgA-Secreting B Cells by Intestinal Dendritic CellsScience, 2006
- The B-Cell System in Inflammatory Bowel Disease2006
- Critical Roles of Activation-Induced Cytidine Deaminase in the Homeostasis of Gut FloraScience, 2002
- Suppressive Role of B Cells in Chronic Colitis of T Cell Receptor α Mutant MiceJournal of Experimental Medicine, 1997
- Human Intestinal B‐Cell Blasts and Plasma Cells Express the Mucosal Homing Receptor Integrin α4β7Scandinavian Journal of Immunology, 1995